Pre-made Elezanumab benchmark antibody ( Whole mAb, anti-RGMA therapeutic antibody, Anti-RGM Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-169

Pre-Made Elezanumab biosimilar, Whole mAb, Anti-RGMA Antibody: Anti-RGM therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Elezanumab (ABT-555) is a monoclonal antibody RGMa inhibitor being investigated to treat spinal cord injuries, multiple sclerosis and acute ischemic stroke.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-169-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Elezanumab biosimilar, Whole mAb, Anti-RGMA Antibody: Anti-RGM therapeutic antibody
INN Name Elezanumab
TargetRGMA
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesAbbVie
Conditions Approvedna
Conditions ActiveMultiple sclerosis;Spinal cord injuries;Stroke
Conditions Discontinuedna
Development Techna